Sloning Launches with the Production of Synthetic Genes
Complete the form below to unlock access to ALL audio articles.
Sloning Biotechnology has announced its market entry. As of July, the company produces synthetic genes using the Slonomics™ technology.
Slonomics™ utilises a library of universal double-stranded DNA building blocks. In a standardised biochemical process, the desired gene is assembled by industrial robotic machines.
In light of the quality of the raw materials and the standardised and automated process, Slonomics™ is considered superior to other gene synthesis techniques.
Sloning claims that, the customer, in particular, benefits from this: estimated delivery times are reliable, and genes can be constructed without difficulty or delay. With this technology, previous restrictions on sequence design are eliminated.
"The challenging research and development phase of the last several years has paid off," stated Dr. Heinz Schwer, the company CEO.
"It is amazing to see how an idea can become a reality. Our Slonomics™ technology is the logical consequence of a growing need for synthetically constructed genes."
"We are sure that this technology will increase the size of the market for such gene products, and that it will soon replace older gene synthesis methods."
Dr. Thomas Waldmann, the business developer at Sloning, commented that, "Slonomics™ fills a technological gap between automated genome sequencing and proteomics."
"In addition, this technology allows for the development of completely new applications in the field of enzyme optimisation, which is also an important contribution to white biotechnology."
